Peer-reviewed article in Oncology & Hematology Review highlights capability of Target Selector™ to detect a key biomarker to qualify lung cancer patients for targeted therapy when tissue biopsy is inadequate SAN DIEGO , April 27, 2018 /PRNewswire/ -- Biocept, Inc.
Letter to the editor highlights capability of Target Selector™ test to detect ROS1, a lung cancer biomarker used to qualify patients for targeted therapies that can improve treatment outcomes SAN DIEGO , May 1, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
SAN DIEGO , May 8, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael
Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ -- Biocept, Inc .
Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO , June 18, 2018 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO , June 25, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an
Expands international distribution of Target Selector™ platform to 17 countries SAN DIEGO , July 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes
